Abbott

189 articles about Abbott

• Banyan Provides Non-Exclusive License of Traumatic Brain Injury (TBI) Biomarkers to Abbott for Use on its Core Laboratory Instruments

  4/4/2019

  With this license, Abbott continues its development of a TBI assessment blood test for the point-of-care and its core laboratory instruments. Financial terms of the agreement were not disclosed.

• Abbott Hosts Conference Call for First-Quarter Earnings - March 20, 2019

  3/20/2019

  Abbott will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.

• Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

  3/19/2019

  Alinity m will allow labs to meet the growing demand for infectious disease testing by offering increased efficiency and market-leading speed and accuracy

• New Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump

  3/17/2019

  New MOMENTUM 3 data show the best outcomes seen in a randomized controlled clinical trial for left ventricular assist device (LVAD) therapy

• New Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device

  3/17/2019

  New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy

• Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device

  3/14/2019

  Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

• Abbott's Latest Diagnostics Technology, Alinity, Selected by Regional Medical Laboratory, Inc. to Deliver Benefits to Hospitals and Patients

  3/5/2019

  Regional Medical Laboratory, Inc., which is part of the Ascension network, partners with Abbott, the global health leader, to advance lab capabilities and help improve health outcomes

• Abbott to Present at Barclays Global Healthcare Conference

  2/25/2019

  Brian Yoor, executive vice president of finance and chief financial officer, will present at 1:05 p.m. Central time.

• Abbott Declares 381st Consecutive Quarterly Dividend

  2/22/2019

  The board of directors of Abbott declared a quarterly common dividend of 32 cents per share.

• Abbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, to Accelerate Hepatitis B Care

  2/20/2019

  New point-of-care rapid test identifies and helps make effective care more accessible for millions of people living with hepatitis B, in support of World Health Organization (WHO) hepatitis targets

• Abbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin

  2/20/2019

  Abbott (NYSE: ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system).

• Abbott Reports 2018 Results and Issues Strong Forecast for 2019

  1/23/2019

  Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent

• Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation

  1/21/2019

  With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation

• Japanese Red Cross Society Selects Abbott Technology to Screen Country's Blood and Plasma Supply

  1/17/2019

  Long-term agreement between japanese red cross society and abbott brings together two global leaders in blood and plasma screening, helping ensure a safe and efficient blood supply across japan

• Abbott To Acquire Cephea Valve Technologies, Inc.

  1/16/2019

  Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc.

• Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India

  1/11/2019

  Abbott to supply rapid diagnostic tests critical for malaria detection and surveillance, technical expertise and funding support

• Get Bubbly this New Year with Abbott's New Pedialyte® Sparkling Rush™ Powder Packs

  12/19/2018

  - From flu season to air travel, the holidays can be a time for dehydration

• Abbott to Present at the 37th J.P. Morgan Healthcare Conference

  12/11/2018

  Abbott will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019. Brian Yoor, executive vice president of finance and Chief Financial Officer, will present at the conference at 11 a.m. Central time.

• Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms

  12/3/2018

  Today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments.

• Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC

  11/14/2018

  Baker Mills' offer price of $57.00 per share in cash is approximately 22 percent lower than the $72.79 closing price of Abbott common shares on Nov. 9, 2018